Sugi Predict

Sugi Predict / Compounds / SCHEMBL533540

SCHEMBL533540

SCHEMBL533540

Cc1ccc(C(=O)O)cc1Nc1nccc(-c2cccnc2)n1

nearest known ligand 0.71

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 11/20 0.71
▸ PDGFRA P16234 11/20 0.71
▸ BCR P11274 9/20 0.71
▸ PDGFRB P09619 6/20 0.71
▸ PRKCA P17252 4/20 0.71
▸ EGFR P00533 4/20 0.71
▸ JAK3 P52333 1/20 0.66
▸ BTK Q06187 1/20 0.66
▸ ITK Q08881 1/20 0.66
▸ KIT P10721 4/20 0.65
▸ CAMKK2 Q96RR4 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29707254 1.00 ABL1 (0.71) ABL1PDGFRABCRPDGFRBPRKCA
SCHEMBL12715062 0.91 ABL1 (0.77) ABL1PDGFRABCRPDGFRBPRKCA
SCHEMBL22169873 0.91 CAMKK2 (0.74) ABL1PDGFRABCRPDGFRBPRKCA
SCHEMBL1566674 0.90 ABL1 (0.69) ABL1PDGFRABCRPDGFRBPRKCA
SCHEMBL13531218 0.90 ABL1 (0.69) ABL1PDGFRABCRPDGFRBPRKCA
SCHEMBL1653881 0.90 ABL1 (0.72) ABL1PDGFRABCRPDGFRBPRKCA
SCHEMBL12714522 0.90 ABL1 (0.69) ABL1PDGFRABCRPDGFRBPRKCA
Hydrochloric Acid SCHEMBL1566422 0.89 ABL1 (0.68) ABL1PDGFRABCRPDGFRBPRKCA
SCHEMBL534524 0.89 ABL1 (0.72) ABL1PDGFRABCRPDGFRBPRKCA
SCHEMBL24122638 0.88 ABL1 (0.67) ABL1PDGFRABCRPDGFRBPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036689-A Nilotinib preparation method of nylon 苏州特瑞药业股份有限公司 2026-05-15 — — CN claimed
CN-112745300-A Method for preparing N- (5-carboxyl-2-methylphenyl) -4- (3-pyridine) -2-pyrimidinamine 杭州浙中医药科技有限公司 2021-05-04 — — CN claimed
CN-110078708-B Smo/Bcr-Abl dual-targeting inhibitor and synthetic method and application thereof 东南大学 2020-12-11 — — CN claimed
CN-111329863-A Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia 黄泳华 2020-06-26 — — CN claimed
WO-2015087343-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF NILOTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF LAURUS LABS PRIVATE LIMITED (IN) 2015-06-18 — — WO claimed
CN-102321073-A Preparation method of nilotinib UNIV XI AN JIAOTONG 2012-01-18 — — CN claimed
US-20100016590-A1 NILOTINIB INTERMEDIATES AND PREPARATION THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2010-01-21 — — US claimed
WO-2009109991-A2 NOVEL HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD., (IN) 2009-09-11 — — WO claimed
CN-122036689-A Nilotinib preparation method of nylon 苏州特瑞药业股份有限公司 2026-05-15 — — CN disclosed
EP-4676475-A1 HIV-1P ROTEASE INHIBITORS AND USES THEREOF Purdue Research Foundation (US) 2026-01-14 — — EP disclosed
CN-113968801-B Nilotinib intermediate and preparation method thereof 扬子江药业集团南京海陵药业有限公司 2025-05-02 — — CN disclosed
US-20250057841-A1 KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF HANDA ONCOLOGY, LLC (US) 2025-02-20 — — US disclosed
US-20250049797-A1 KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF HANDA ONCOLOGY, LLC (US) 2025-02-13 — — US disclosed
US-20240366603-A1 KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF HANDA ONCOLOGY, LLC (US) 2024-11-07 — — US disclosed
US-20070093506-A1 Inhibitors of tyrosine kinases BREITENSTEIN WERNER 2007-04-26 — — US disclosed
US-7169791-B2 Inhibitors of tyrosine kinases NOVARTIS AG (CH) 2007-01-30 — — US disclosed
US-20060167015-A1 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) NOVARTIS AG (CH) 2006-07-27 — — US disclosed
CN-1675195-A Tyrosine kinase inhibitors NOVARTIS AG (CH) 2005-09-28 — — CN disclosed
EP-1532138-A1 INHIBITORS OF TYROSINE KINASES Novartis AG (CH) 2005-05-25 — — EP disclosed
WO-2004005281-A1 INHIBITORS OF TYROSINE KINASES NOVARTIS AG (CH) 2004-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093506-A1 Inhibitors of tyrosine kinases ABL1, BTK, FLT3 ABL1 1/4885PDGFRA 382/4885BCR 28/4885
US-20250049797-A1 KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF BRAF, MAP3K15, RAF1 ABL1 448/4885PDGFRA 1245/4885BCR 3530/4885
US-20250057841-A1 KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF BRAF, MAP3K15, RAF1 ABL1 448/4885PDGFRA 1245/4885BCR 3530/4885
US-20100016590-A1 NILOTINIB INTERMEDIATES AND PREPARATION THEREOF ABL1, FLT3, ABL2 ABL1 1/4885PDGFRA 21/4885BCR 5/4885
US-20240366603-A1 KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF SRC, ABL1, MCL1 ABL1 2/4885PDGFRA 1256/4885BCR 196/4885
US-20060167015-A1 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) ABL1, CDK2, CDKN1A ABL1 1/4885PDGFRA 440/4885BCR 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.